Fidelis Capital Partners LLC boosted its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 49.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,960 shares of the company’s stock after acquiring an additional 1,634 shares during the period. Fidelis Capital Partners LLC’s holdings in Zoetis were worth $979,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC lifted its stake in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares during the period. VitalStone Financial LLC bought a new position in Zoetis during the first quarter worth about $37,000. Evermay Wealth Management LLC grew its position in shares of Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the period. Finally, Worth Asset Management LLC acquired a new position in shares of Zoetis during the 1st quarter worth about $26,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Zoetis
In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 2,209 shares of company stock worth $371,293 in the last three months. Insiders own 0.12% of the company’s stock.
Analyst Upgrades and Downgrades
Zoetis Stock Up 1.1 %
Shares of ZTS stock traded up $1.60 on Thursday, hitting $153.11. 4,729,796 shares of the stock were exchanged, compared to its average volume of 2,989,420. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $70.03 billion, a P/E ratio of 30.15, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85. Zoetis Inc. has a fifty-two week low of $148.48 and a fifty-two week high of $201.92. The business has a 50-day moving average of $177.35 and a 200 day moving average of $180.39.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $1.15 EPS. Equities analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current year.
Zoetis Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.13%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- 5 discounted opportunities for dividend growth investors
- Comprehensive PepsiCo Stock Analysis
- What is a Dividend King?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Bear Market Funds to Watch This Year
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.